Novo Nordisk Stock Rebounds 22% in 2026
Written by Emily J. Thompson, Senior Investment Analyst
Source: NASDAQ.COM
- Stock Volatility: Novo Nordisk's stock plummeted 40% in 2025, yet it has rebounded 22% in 2026, reflecting market optimism about its future despite losing market share to competitors last year.
- Profitability Decline: The company's earnings per share fell from $6.53 in Q1 2025 to $4.50 by Q3, a nearly 30% drop, indicating significant profitability challenges that could affect investor confidence.
- Strong Prescription Demand: In its second week on the market, prescriptions for Novo Nordisk's oral Wegovy reached 18,000, dwarfing the 8,000 for Lilly's Zepbound, suggesting robust demand for convenient medication forms that may drive future sales growth.
- Attractive Valuation: With a price-to-earnings ratio of 17 and strong drug demand, analysts predict continued stock recovery in 2026, although the Motley Fool's analyst team did not include it in their list of top investment stocks.
Analyst Views on NVO
Wall Street analysts forecast NVO stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for NVO is 54.67 USD with a low forecast of 42.00 USD and a high forecast of 70.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Analyst Rating
4 Buy
3 Hold
1 Sell
Moderate Buy
Current: 63.980
Low
42.00
Averages
54.67
High
70.00
Current: 63.980
Low
42.00
Averages
54.67
High
70.00
About NVO
Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
